+33 (0)251 252 000 contact@inflectisbioscience.com

Board of Directors


Philippe GUÉDAT, PhD

Dr Mark Pykett is Chief Executive Officer of Myrtelle, Inc., a private biotechnology company.  He has over 25 years of pharmaceutical industry executive management experience.  Prior to Myrtelle, Dr. Pykett was Chief Scientific Officer at PTC Therapeutics, CEO of Agilis Biotherapeutics, CEO of Navidea Pharmaceuticals, President and Chief Operating Officer of Alseres Pharmaceuticals, President of CyGenics and CEO of Cytomatrix.  He has also been a board member of both public and private organizations, including the biotech companies Pharming Group and Exubrion Therapeutics and the not-for-profit organization HealthBuilders developing healthcare infrastructure in Rwanda.  Dr. Pykett holds a BA from Amherst College, a VMD and PhD from the University of Pennsylvania, and an MBA from Northeastern University.  He also completed post-doctoral work at the University of Pennsylvania and Harvard University. Mark joined the Board of Directors of InFlectis BioScience in October 2021 as Chairman of the Board.


Dr Pierre Miniou has over 20 years of international experience in business development and licensing in the biopharmaceutical industry with the signing of many partnering and license agreements. He has experience of senior management having been the head of the patent department of Pierre Fabre Laboratories, a member of the Executive Committee of Vivalis (now Valneva) and Director of Vivalis Toyama (Japan). Pierre holds a Master’s degree and Engineering degree in Biotechnology from the School of Biotechnology of Strasbourg and a PhD in Molecular and Cellular Biology from the Louis Pasteur University of Strasbourg. He is also graduated from the CEIPI (Centre for International Studies of Industrial Property) in Strasbourg and holds a MBA (Audencia, Nantes).



Jérôme Guéret has a deep experience in venture capital industry and financing. Since 2013, Jérôme is partner at GO Capital, one of the leading high tech venture capital firms in France. Before joining GO Capital, Jérôme was CEO of a high tech electronic company sold to EDF-EN Group in 2008 and was former television VP marketing at Orange Group in 2003. He managed projects and drove strategic execution on new business lines and emerging markets, specifically in telecom and energy sectors. Jerome has a degree from Kedge Business School and an Executive MBA from ESCP Europe.


Taro Inaba

Taro Inaba is co-Founder and Managing Partner of Remiges Ventures. He has over 27 years of business development and venture investment experience. Currently he holds positions as a board member at Inflectis Bioscience, Omeicos Ophthalmics, Mitoconix Bio, Digestome Therapeutics and Aqross Therapeutics. Prior to establishing Remiges in 2014, he spent 23 years at Mitsui & Co where he spent the last 13 years being engaged in investment activities including a position as President & CEO at Mitsui & Co Venture Partners in Menlo Park from 2008 to 2009. While he was at Mitsui, he holds positions as a board member in 11 companies including Actimis Pharmaceuticals, Boston Biomedical and Hutchison Meidppharma. Taro is co-Founder of Koinobori a philanthropic entity focusing on mitochondrial disease. Taro holds a B.E. in Polymer Chemistry, Kyoto University and MBA from European University. He is a CFA charter holder.